TransCode Therapeutics, Inc. annonce des changements au sein de son conseil d'administration et de ses comités

TransCode Therapeutics, Inc. a annoncé la nomination de Jack E. Stover au sein de son conseil d'administration. M. Stover ...
Investing.com France

TransCode Therapeutics nomme Jack E. Stover à son conseil d’administration

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), une société en phase clinique spécialisée dans l’immuno-oncologie et les traitements à base d’ARN pour les cancers avancés, a annoncé lundi la nomi ...
TipRanks on MSN

TransCode Therapeutics strengthens board with veteran financial expert

TransCode Therapeutics ( ($RNAZ) ) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences ...

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover ...

Investornewsbreaks Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover To Board Of Directors

Appoints Jack E. Stover To Board Of Directors. TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors, where he will serve on the Audit Committee ...
Hosted on MSN

TransCode announces collaboration for phase 2a trial

TransCode Therapeutics ( (RNAZ)) has shared an announcement. On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead ...
scmp.com

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs pipeline

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech ...
Seeking Alpha

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...
FierceBiotech

TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...
Yahoo Finance

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique ...

TransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma Philippe Calais, PharmD, PhD, ...
Finanznachrichten

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA ...